KTTA: Pasithea Therapeutics P/S Multiple
The venture potential of Pasithea Therapeutics (KTTA) is based on small molecule patents, as confirmed by the daily chart from the GURU.Markets service. The price-to-sales ratio, where the value 39.40 indicates the current figure, correlates with significant pricing power in the neurobiology segment. Strict FDA regulations and the high cost of clinical trials serve as business protections, creating a substantial barrier to entry for new players.
Analytical breakdowns for Pasithea Therapeutics (KTTA)
- current quotes and average value forecast:
- market capitalization information:
- balance sheet equity data:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Pasithea Therapeutics|KTTA - Long-Term Debt to Capital|Current Liabilities to Capital pasitheaclinics.com|KTTA - Company Debts|Debt to Net Assets Ratio Pasithea|KTTA - Company Long-Term Debts|Company Short-Term Debts Pasithea Therapeutics|Critical Liquidity Ratio pasitheaclinics.com
- earnings and valuation multiples information:
KTTA - Net Profit|Expected Net Profit Pasithea Therapeutics|KTTA - Price to Earnings Ratio|Forward P/E Multiple pasitheaclinics.com|KTTA - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Pasithea|KTTA - Operating profit EBITDA|Net earnings per share for the last four quarters Pasithea Therapeutics|KTTA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months pasitheaclinics.com|KTTA - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Pasithea Therapeutics
- sales revenue and business income indicators:
Fundamental company analysis:Pasithea Therapeutics Corp, KTTA
Maximum outsourcing of synthesis and testing at Pasithea Therapeutics (KTTA) minimizes capital expenditures by shifting operational risk to external contractors. The market capitalization-to-revenue ratio, represented by the fundamental P/S, allows investors to decouple price volatility from static sales, determining the premium paid for a business model with a lean management structure.
Competing companies
BIIB - Price to Sales|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|P/S Multiple Regencell Bioscience Ltd RGC|AXSM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Corp)|XENE (Xenon Pharmaceuticals) - Market Cap to Revenue|VKTX: Market Cap to Sales Volume|SUPN (Supernus) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|HRMY - Price to Sales|Price-to-Revenue Ratio Biohaven Ltd. BHVN|Market Capitalization-to-Revenue Ratio AMLX|Trevi Therapeutics, Inc. - P/S Multiple|PRAX - P/S Multiple|Anavex Corp (AVXL) - Price-to-Revenue Ratio|Price-to-Sales Ratio CBLL (CeriBell EEG)|PRTA (Prothena Biosciences) - P/S Multiple|Price to Sales Alector Therapeutics ALEC|Market Cap to Revenue ANNX (Annexon)|P/S Multiple omeros.com (OMER)|Neurogene Corp - Market Cap to Revenue|Market Cap to Sales Volume ACIU (AC Immune Inc)|Voyager Therapeutics - P/S Multiple|Price-to-Revenue Coefficient neumoratx.com NMRA|SCLX: P/S Multiple|Market Cap to Revenue Tevogen Bio Holdings Inc.|Price-to-Revenue Ratio Alpha Cognition Inc|Cognition Therapeutics Inc. (CGTX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|P/S Multiple cassavasciences.com (SAVA)|Assertio - Market Cap to Revenue|Market Cap to Sales Volume COYA (Coya Therapeutics Inc)|VTGN: Market Cap to Revenue|Ovid Therapeutics Inc. - Market Cap to Sales Volume|ABOS: P/S Multiple|cervomed.com (CRVO) - P/S Multiple|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|Market Cap to Revenue Ratio CLNN (Clene Nanomedicine)|P/S Multiple PEPG|JUNS - Price to Sales|Relmada Therapeutics - Market Cap to Revenue|P/S Multiple annovisbio.com ANVS|GRCE - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio AIFF (Firefly Neuroscience, Inc.)|anewmeds.com (KLTO) - Price-to-Revenue Ratio|Price to Sales NeuroSense Therapeutics Ltd. (NRSN)|Price-to-Revenue Ratio Reviva Pharmaceuticals|MetaVia, Inc. - Price-to-Sales Ratio|P/S Multiple NRXS|P/S Multiple heliusmedical.com (HSDT)|Price-to-Revenue Ratio Passage Bio PASG|Price-to-Revenue Coefficient Neuphoria Therapeutics, Inc. (NEUP)|Minerva Neurosciences - P/S Multiple|Price-to-Revenue Coefficient athira.com ATHA|ADXN (Addex Therapeutics Ltd) - Market Cap to Revenue|ALZN: Market Cap to Sales Volume|CYCN (Cyclerion Therapeutics Inc.) - P/S Multiple|PTIX: Market Capitalization-to-Revenue Ratio|P/S Multiple CRGT|ATXI - Price to Sales|P/S Multiple BCLI (BrainStorm Cell Therapeutics)|P/S Multiple Cara Therapeutics Inc. CARA|CHRO: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ELYM (Eliem Therapeutics)|ITCI (intracellulartherapies.com) - Market Cap to Revenue|LBPH: Market Cap to Sales Volume|MRNS (Marinus Pharmaceuticals, Inc.) - P/S Multiple|NKGN: Market Capitalization-to-Revenue Ratio|P/S Multiple NRBO|SAGE - Price to Sales|Price-to-Revenue Ratio Synaptogenix, Inc. SNPX|Market Capitalization-to-Revenue Ratio TRVN|Vigil Neuro - P/S Multiple|WENA - P/S Multiple|Cerevel (CERE) - Price-to-Revenue Ratio
